Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 12, 2024, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval Selexipag for Injection, 1,800 mcg/vial".
Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 12, 2024, titled "Alembic Pharmaceuticals receives USFDA Tentative Approval Selexipag for Injection, 1,800 mcg/vial".